
Keller Lab
Mechanism-based Cancer Therapies
Profile
Cancer originates from normal cells through genetic and epigenetic alterations. By employing forward genomic screening we start from a known gene mutation or cancer-associated condition and investigate the path that results in a manifest malignancy. Major further focus areas of the lab include: oncoprotein-induced disturbance of post-translational protein modifications, in particular SUMOylation, and sensing of DNA damage; constitutively activated B-cell receptor and chemokine receptor signaling; and molecular cancer imaging and theranostics.
Team
Group Leader
Prof. Dr. med. Ulrich Keller
Team
Markus Schick, M.Sc., Postdoc
Matthias Wirth, PD Dr. rer. nat., Scientist
Stefan Habringer, Dr. med. Dr. univ., Clinician scientist
Jolanta Slawska, M.Sc., Technical assistant (affiliation: TUM)
Konstandina Isaakidis, B.Sc., Technical assistant
Veronika Schulze, M.Sc., Technical assistant
Stefanos Alexandros Bamopoulos, Clinician scientist
Nikita Nikita, PhD student
Le Zhang, MD student
Minh Ho, B.Sc., Technical assistant
Yingfen Hong, MD student (TUM)
Josefina Doffo, M.Sc., PhD student (affiliation: TUM)
Elena Rohleder, Dr. med., Clinician scientist
Sven Liebig, Clinician scientist
Francis Baumgartner, Dr. med., Clinician scientist
Uta Demel, Dr. med., Clinician scientist
Richard Lewis, MD student (affiliation: TUM/Charité)
Stavroula Litsiou, Pharmacist, PhD student
Laura Schmalbrock, Dr. med., Clinician scientist
Enio Gjerga, M.sc., Bioinformatician, Postdoc
Research
Myc-associated cancer biology
Functional genomic screening
Aberrant Ub/SUMO activity in cancer
Chemokine receptor signaling
Functional imaging and theranostics
Publications
Funding
- Deutsche Forschungsgemeinschaft (SFB 824, SFB 1335)
- Deutsche Krebshilfe
- Sander Stiftung
- EU/BMBF Horizon 2020
- German Cancer Consortium (DKTK)
- Stiftung Charité
- Berlin Institute of Health (BIH)
- Berliner Krebsgesellschaft